Evidence map›Paper›PMID 35462303›Full record

ReviewClinical neurology and neurosurgery2022

Cerebral venous thrombosis during the COVID-19 Pandemic: A multi-center experience.

Ricardo A Domingo, Andres Ramos-Fresnedo, Carlos Perez-Vega, Shashwat Tripathi, Michael W Pullen, Jaime L Martinez, Young M Erben, James Meschia, Rabih G Tawk

Open access · greenAbstract readReview
In one paragraph

Review in Clinical neurology and neurosurgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Retinal vascular occlusions in COVID-19 infection and vaccination: a literature review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ricardo A DomingoNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Andres Ramos-FresnedoNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Carlos Perez-VegaNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Shashwat TripathiNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Michael W PullenNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Jaime L MartinezNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA.
Young M ErbenNeurology Department, Mayo Clinic, Jacksonville, Florida, USA.
James MeschiaNeurology Department, Mayo Clinic, Jacksonville, Florida, USA.
Rabih G TawkNeurologic Surgery Department, Mayo Clinic, Jacksonville, Florida, USA. Electronic address: tawk.rabih@mayo.edu.
Mayo Clinic in Florida · USJacksonville College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the clinical characteristics and outcomes of CVT in patients with history of recent COVID-19 infection or vaccination.

methodsWe reviewed demographic, clinical, and radiographic characteristics of non-pyrogenic, non-traumatic CVT cases at our multi-center institution between March 2020 and December 2021. Patients were grouped according to their history of recent COVID-19 infection or vaccination into group-I (+COVID-19 association) and group-II (-COVID-19 association).

resultsFifty-one patients with CVT were included, of which 14 (27.4%) had a positive COVID-19 association: 10 with infection and 4 with mRNA-COVID-vaccine. Nine patients in group-I had COVID-19 infection or vaccine within 30 days of CVT diagnosis, including 3 patients with active infection at the time of CVT diagnosis. Half of the patients in group-I (n = 7,50.0%) and 32.4% (n = 12) of group-II were male, and mean age was 52.6 years in group-I and 51.4 years in group-II. Fever at presentation was noted in one patient who had active COVID infection (I=1 (7.1%), II= 0 (0%)). Higher rates of comorbidities were observed in group-II: hypertension (I= 2 (14.3%), II= 13 (35.1%)), deep venous thrombosis(I=1(7.1%), II= 10 (27.0%)), pulmonary emboli (I=1(7.1%), II= 8(21.6%)), or stroke(I=0(0%), II= 6(16.4%)). Three patients had thrombocytopenia at the time of CVT diagnosis (5.4%) and most patients (n = 37, 72.5%) were treated medically with anticoagulation. Complication rate during hospitalization was 17.6% (n = 6), and no mortality was noted.

conclusionTwenty-seven percent of CVT patients were associated with COVID-19 infection or vaccination, and the majority presented within 30 days of infection/vaccination.

Indexed as

COVID-19Intracranial ThrombosisVaccinesVenous ThrombosisFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPandemicsVaccinesCerebral vein thrombosisCoronavirusCOVIDHemorrhageStroke

Identifiers

PMID35462303
PMCPMC9017058
OpenAlexW4224250137

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.